Blog
RSS FeedPosted by Michael Wonder on 19 Oct 2023
Health economic assessment of Spinraza for type 5q spinal muscular atrophy
18 October 2023 - TLV has produced a health economic knowledge base for the regions for Spinraza (nusinersen sodium) for the ...
Posted by Michael Wonder on 12 Oct 2023
Health economic assessment of the gene therapy Hemgenix in severe and moderate haemophilia B
11 October 2023 - TLV has developed a health economic knowledge base for the regions for the gene therapy Hemgenix (etranacogene ...
Posted by Michael Wonder on 20 Jun 2022
Givlaari is included in the high-cost protection with limitation
17 June 2022 - Givlaari (givosiran) is included in the high-cost protection with limited subsidy to reduce attacks in patients with ...
Posted by Michael Wonder on 21 Apr 2021
Additional analysis of Luxturna in the treatment of visual impairment caused by hereditary eye disease
21 April 2021 - TLV has made a supplementary analysis to the previous evaluation of Luxturna, as Novartis has submitted new ...
Posted by Michael Wonder on 15 Mar 2021
Health economic assessment of Zolgensma in spinal muscular atrophy
12 March 2021 - TLV has produced a health economic assessment for the regions for Zolgensma (onasemnogene abeparvovec) in the treatment ...
Posted by Michael Wonder on 12 May 2020
Third evaluation within the FINOSE collaboration
12 May 2020 - Together with the corresponding authorities in Finland and Norway, TLV has produced a joint evaluation report ...
Posted by Michael Wonder on 11 May 2020
Health economic assessment of gene therapy Zynteglo in transfusion-dependent beta-thalassemia
11 May 2020 - TLV has developed a health-economic knowledge base for the Zynteglo gene therapy (autologous CD34-positive cells expressing the ...
Posted by Michael Wonder on 30 May 2019
Health economic assessment of Luxturna in the treatment of visual impairment caused by hereditary eye disease
29 May 2019 - TLV has produced a health economic knowledge base for the region for the drug Luxturna (voretigene ...
Posted by Michael Wonder on 23 May 2019
Health economic assessment of Tegsedi in hereditary transthyretin amyloidosis
17 May 2019 - TLV has produced a health economic knowledge base for the regions for Tegsedi (inotersen) that treat hereditary ...